TMCnet News
EPIZYME, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 2, 2014, Epizyme, Inc. (the "Company") announced that Jason Rhodes had submitted his resignation as President and Chief Financial Officer of the Company, effective September 30, 2014, to pursue opportunities in venture capital. Mr. Rhodes will remain as President and Chief Financial Officer through September 30, 2014. Mr. Rhodes has agreed to serve as a consultant to the Company for a three-month period following his resignation under the terms of a consulting agreement entered into with the Company on September 2, 2014 that will become effective upon the effectiveness of Mr. Rhodes' resignation. Under the terms of the consulting agreement, Mr. Rhodes will provide consulting services to the Company for up to 30 hours per month for a consulting fee of $400 per hour to assist with the transition. Item 7.01 Regulation FD Disclosure On September 2, 2014, the Company issued a press release relating to Mr. Rhodes' resignation. A copy is furnished herewith. Item 9.01 Financial Statements and Exhibits (d) Exhibits 10.1 Consulting agreement dated as of September 2, 2014 by and between the Registrant and Jason P. Rhodes 99.1 Press release issued by the Company on September 2, 2014* * The exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed. -------------------------------------------------------------------------------- |